# A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC)

> **NCT01655992** · PHASE3 · TERMINATED · sponsor: **Fudan University** · enrollment: 386 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** capecitabine
- **DRUG:** S1 generic

## Key facts

- **NCT ID:** NCT01655992
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-01
- **Primary completion:** 2017-10
- **Final completion:** 2017-10
- **Target enrollment:** 386 (ESTIMATED)
- **Why stopped:** The sponsor decided to stop the study.
- **Last updated:** 2018-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01655992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01655992, "A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC)". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT01655992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*